Cardiol receives clearance from regulators in Brazil, Mexico, and U.S. to speed up patient registry

Name: Cardiol receives clearance from regulators in Brazil, Mexico, and U.S. to speed up patient registry
Uploaded: 2022-03-01T14:19:00Z
Description: Cardiol receives clearance from regulators in Brazil, Mexico, and U.S. to speed up patient registry

Proactive Published 01/03/2022

Share X in f @

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Steve Darling from Proactive to bring news the company has received clearance from the FDA and regulatory agencies in the U.S. Brazil and Mexico to modify the inclusion criteria for the LANCER trial to broaden the patient eligibility for enrolment.

Elsley telling Proactive the LANCER is designed to evaluate the efficacy and safety of CardiolRx and they hope to achieve over 50% patient recruitment by the end of the first half of 2022. The Company also announced plans to expand the clinical trial infrastructure to include up to an additional 20 clinical research centres.